Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Serum insulin-like factor 3 levels are reduced in former androgen users suggesting impaired Leydig cell capacity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effect of Anabolic-Androgenic Steroid Abuse on the Contact Activation System

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Marie Louise Johansen
  • Jaime Ibarrola
  • Amaya Fernández-Celis
  • Morten Schou
  • Mette Pauli Sonne
  • Maria Refsgaard Holm
  • Jon Rasmussen
  • Flemming Dela
  • Frederic Jaisser
  • Jens Faber
  • Patrick Rossignol
  • Natalia Lopez-Andres
  • Caroline Kistorp
View graph of relations

Activation of the mineralocorticoid receptor (MR) may promote dysfunctional adipose tissue in patients with type 2 diabetes, where increased pericellular fibrosis has emerged as a major contributor. The knowledge of the association between the MR, fibrosis and the effects of an MR antagonist (MRA) in human adipocytes remains very limited. The present sub-study including 30 participants was prespecified as part of the Mineralocorticoid Receptor Antagonist in type 2 Diabetes (MIRAD) trial, randomizing patients to either high dose eplerenone or placebo for 26 weeks. In adipose tissue biopsies, changes in fibrosis were evaluated by immunohistological examinations and by the expression of mRNA and protein markers of fibrosis. Treatment with an MRA reduced pericellular fibrosis, synthesis of the major subunits of collagen type I and VI, and the profibrotic factor α-smooth muscle actin, as compared to placebo in subcutaneous adipose tissue. Furthermore, we found decreased expression of the MR and downstream molecules neutrophil gelatinase-associated lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA. In conclusions, we present original data demonstrating reduced fibrosis in adipose tissue with inhibition of the MR, which could be a potential therapeutic approach to prevent the extracellular matrix remodeling of adipose tissue in type 2 diabetes.

Original languageEnglish
JournalDiabetes
Volume70
Issue number1
Pages (from-to)196-203
Number of pages8
ISSN0012-1797
DOIs
Publication statusPublished - Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 by the American Diabetes Association.

Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

ID: 61433852